Crossref
Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect
Neurological Disorders and Therapeutics · 2017
DOI: 10.15761/ndt.1000103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Disorders and Therapeutics, 2017. Verfasst von Margherita Gardinetti und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gardinetti, M., Barcella, V., Frigeni, B., Frigo, M., Fusco, M. L., & Rottoli, M. (2017). Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect. Neurological Disorders and Therapeutics. https://doi.org/10.15761/ndt.1000103
Vancouver
Gardinetti M, Barcella V, Frigeni B, Frigo M, Fusco ML, Rottoli M. Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect. Neurological Disorders and Therapeutics. 2017. doi:10.15761/ndt.1000103
BibTeX
@article{Gardinetti2017,
author = {Gardinetti, Margherita and Barcella, Valeria and Frigeni, Barbara and Frigo, Maura and Fusco, Maria L and Rottoli, Mariarosa},
title = {Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect},
journal = {Neurological Disorders and Therapeutics},
year = {2017},
doi = {10.15761/ndt.1000103}
}
EUVIMED